Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
Grommes C, Gavrilovic I, Kaley T, Nolan C, Omuro A, Wolfe J, Pentsova E, Hatzoglou V, Mellinghoff I, DeAngelis L. Updated results of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Journal Of Clinical Oncology 2017, 35: 7515-7515. DOI: 10.1200/jco.2017.35.15_suppl.7515.Peer-Reviewed Original ResearchSecondary CNS lymphomaProgression-free survivalMedian progression-free survivalALT elevationCNS lymphomaAdverse eventsClinical responseGrade 4 adverse eventsRecurrent/refractory diseaseAggressive primary brain tumorCerebrospinal fluid involvementCNS lymphoma patientsGrade 5 eventsManageable adverse eventsGrade 3 toxicityMedian overall survivalMethotrexate-based chemotherapyEnd-organ functionNormal end-organ functionSingle-agent ibrutinibUrinary tract infectionPrimary brain tumorsPromising clinical responsesMantle cell lymphomaCommon toxicities